Jupiter Neurosciences Amends Yorkville Financing Agreement Terms

The latest update is out from Jupiter Neurosciences, Inc. ( (JUNS) ).

On February 20, 2026, Jupiter Neurosciences, Inc. amended the terms of its financing arrangements with YA II PN, LTD (Yorkville), linked to a previously disclosed Standby Equity Purchase Agreement and related convertible promissory notes under which Yorkville had advanced up to $6.0 million in two tranches. The Omnibus Amendment extended the start of required monthly installment payments on the amended and restated convertible notes to April 1, 2026, shifted to a variable payment schedule, and updated rules on issuing advance notices, while preserving the company’s option to make installments in cash, through advance repayments, or a combination, thereby easing near-term repayment pressure and providing added flexibility in managing its capital structure.

The most recent analyst rating on (JUNS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.

More about Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a biopharmaceutical company focused on developing neurological therapies, operating in a capital-intensive industry that often relies on structured financing to support research, clinical development, and corporate operations. The company accesses external funding through instruments such as standby equity purchase agreements and convertible promissory notes to maintain financial flexibility and support its strategic initiatives.

Average Trading Volume: 279,553

Technical Sentiment Signal: Strong Sell

Current Market Cap: $19.24M

See more insights into JUNS stock on TipRanks’ Stock Analysis page.